Abstract
SARS-CoV-2 Omicron surged as a variant of concern in late 2021. Subsequently, several distinct Omicron variants have appeared and overtaken each other. We combined variant frequencies and infection estimates from a nowcasting model for each US state to estimate variant-specific infections, attack rates, and effective reproduction numbers (Rt). BA.1 rapidly emerged, and we estimate that it infected 47.7% of the US population between late 2021 and early 2022 before it was replaced by BA.2. We estimate that BA.5, despite a slower takeoff than BA.1, infected 35.7% of the US population, persisting in circulation for nearly 6 months. Other Omicron variants - BA.2, BA.4, and XBB - together infected 30.7% of the US population. We found a positive correlation between the state-level BA.1 attack rate and social vulnerability and a negative correlation between the BA.1 and BA.2 attack rates. Our findings illustrate the complex interplay between viral evolution, population susceptibility, and social factors during the Omicron emergence in the US.
Competing Interest Statement
NDG is a paid consultant for BioNTech.
Funding Statement
This project is supported by Cooperative Agreement NU38OT000297 from the Centers for Disease Control and Prevention (CDC) and the Council of State and Territorial Epidemiologists (CSTE), SHEPheRD Contract 200-2016-91779 from the CDC, and the CDC Broad Agency Announcement Contract 75D30122C14697. This work does not necessarily represent the views of the CDC or CSTE.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used (or will use) ONLY openly available human data that were originally located at: https://github.com/rafalopespx/Variant_infections_rate
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Co-senior authors
Figure 1 updated; Table 1 updated; supplementary tables updated
Data Availability
All data produced are available online at: https://github.com/rafalopespx/Variant_infections_rate
